We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ISA:BVCInterconexion Electrica SA ESP Analysis

Data as of 2026-03-15 - not real-time

SEK 0.23

Latest Price

8/10Risk

Risk Level: High

Executive Summary

ISAB is trading at SEK 0.232, well beneath its 20‑day (0.269), 50‑day (0.340) and 200‑day (0.431) simple moving averages, signaling a clear bearish price environment. The 14‑day RSI sits at 39.5, hinting at oversold conditions, while the MACD line remains under its signal, confirming downward momentum. Current price hovers just above the identified support at 0.172 and faces resistance near 0.346, with a 30‑day volatility of roughly 147 %, indicating large price swings. Volume has been stable but thin, reflecting limited liquidity.
Fundamentally, the company posted a 13 % revenue contraction to SEK 3.0 M and generated an operating loss of over SEK 20 M, driving negative EBITDA and free cash flow. Despite an impressive gross margin of 85 %, operating margins are deeply negative and cash burn exceeds the SEK 2.8 M cash balance, leaving the balance sheet thin but debt‑free. The price‑to‑book ratio of 1.25 and price‑to‑sales of 3.0 suggest the market is not rewarding earnings, as the stock carries no dividend and a PE of zero. Although the broader market sentiment is in “Greed” mode (Fear‑Greed Index 72.9), the stock’s high drawdown, modest beta and sector‑specific regulatory exposure keep the upside limited.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • price below all major SMAs
  • bearish MACD and RSI approaching oversold
  • thin liquidity near support

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • persistent operating losses
  • high cash burn vs cash reserves
  • elevated volatility and drawdown

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • potential niche market demand for inhalation research tools
  • strong gross margin but lack of profitability
  • regulatory approvals required for product expansion

Key Metrics & Analysis

Financial Health

Revenue Growth-13.10%
ROE-134.85%
ROA-63.29%
P/B Ratio1.3
Op. Cash FlowSEK-10786000
Free Cash FlowSEK-6981000
Industry P/E26.2

Technical Analysis

TrendBearish
RSI39.5
SupportSEK 0.17
ResistanceSEK 0.35
MA 20SEK 0.27
MA 50SEK 0.34
MA 200SEK 0.43
MACDBearish
VolumeStable
Fear & Greed Index72.88

Valuation

GradeUndervalued
TypeValue

Risk Assessment

Beta0.56
Volatility146.90%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.